share_log

PreveCeutical Enters Into Loan Agreements

PreveCeutical Enters Into Loan Agreements

PreveCeutical進入貸款協議
newsfile ·  06/18 04:22

Vancouver, British Columbia--(Newsfile Corp. - June 17, 2024) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical") announces that it has entered into a series of unsecured, non-convertible and interest-free loan agreements with, the Company's Chief Executive Officer, interim Chief Financial Officer and Chair, Stephen Van Deventer, and the Company's former President and director, Kimberly Van Deventer (collectively, the "Lenders"), in the aggregate amount of $297,731.00 (the "Loans").

不列顛哥倫比亞省溫哥華(Newsfile Corp. - 2024年6月17日)- PreveCeutical Medical Inc.(CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) ("公司計劃議程PreveCeutical本公司宣佈已與首席執行官、臨時財務總監和董事長史蒂芬·範德文特以及公司前總裁兼董事金伯利·範德文特(統稱"公司利益相關方")簽訂了一系列未擔保、不可轉換、零利率的貸款協議,總金額爲297,731.00美元("貸款")。放貸方"),總金額爲297,731.00美元("貸款").

The proceeds of the Loans are intended to be used for working capital purposes.

貸款的所得將用於營運資本。

Stephen Van Deventer's participation is considered to be a "related party transaction" as defined under Multilateral Instrument 61-101 - Protection of Minority Security Holders in Special Transactions ("MI 61-101"). The Company has relied on the exemption from the minority shareholder approval requirement of MI 61-101 contained in section 5.7(1)(f) of MI 61-101 in respect of such insider participation.

史蒂芬·範德文特的參與被視爲是《多邊工具61-101 - 》("MI 61-101") 中所定義的"利益關聯方交易"。董事會和全由獨立董事組成的特別委員會(“特別委員會”)批准的該安排計劃的背景和支持該安排的原因(“背景”);("mi 61-101公司已依據多邊工具61-101中的5.7(1)(f)條所規定的豁免規定,就上述內幕人士的參與豁免少數股東批准要求。

About PreveCeutical

關於PreveCeutical

PreveCeutical is a health sciences company focused on developing innovative options for preventive and curative therapies utilizing organic and nature identical products. The Company aims to be a leader in the preventive health sciences sector.

PreveCeutical 是一家專注於開發利用有機和天然同源產品進行預防和治療的創新選項的健康科學公司。該公司旨在成爲預防衛生科學領域的領導者。

With the completion of three of its research programs, the Company is actively working on the development, clinical trials, and commercialization of its products; and has filed a number of provisional patent applications to protect the intellectual property from its research programs.

公司已完成三個研究項目,正在積極開展產品開發、臨床試驗和商業化,並已提交多項臨時專利申請以保護研究項目的知識產權。

For more information about PreveCeutical, please visit our website or follow us on Twitter and Facebook.

欲了解更多PreveCeutical的資訊,請訪問我們的網站或關注我們的Twitter和Facebook。

On behalf of the Board of Directors of PreveCeutical

謹代表PreveCeutical董事會

Stephen Van Deventer, Chairman, Chief Executive Officer and interim Chief Financial Officer

董事長、首席執行官兼臨時財務總監 Stephen Van Deventer

For further information, please contact:

如需更多信息,請聯繫:

Stephen Van Deventer: +1 604 306 9669

Stephen Van Deventer:+1 604 306 9669

Or Investor Relations ir@preveceutical.com

或投資者關係業務ir@preveceutical.com

Forward-Looking Statements

前瞻性聲明

Cautionary Note Regarding Forward-Looking Statements: This release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws. Forward-looking statements relate to future events or future performance and reflect the expectations or beliefs of management of the Company regarding future events. Generally, forward-looking statements and information can be identified using forward-looking terminology such as "intends" or "anticipates", or variations of such words and phrases or statements that certain actions, events or results "may", "could", "should", "would" or "occur". This information and these statements, referred to herein as "forward‐looking statements", are not historical facts, are made as of the date of this news release and include without limitation, statements regarding discussions of future plans, estimates and forecasts and statements as to management's expectations and intentions with respect to, among other things: the Company's anticipated use of proceeds of the Loans; and the Company's plans relating to the development, clinical trials and commercialization of its products.

關於前瞻性聲明的警示: 本文包含可能構成適用加拿大證券法規中的前瞻性信息的某些聲明和信息。前瞻性聲明涉及未來事件或未來表現,並反映公司管理層對未來事件的預期或信念。一般而言,可以使用"打算"或"預計"這類意思的前瞻性詞彙,或者使用此類詞語和短語的變體或某些行動、事件或結果"可能"、"可能會"、"應該"、"將"或"發生"的聲明,來識別前瞻性聲明和信息。本文中的信息和這些聲明(以下稱爲"前瞻性聲明")不是歷史事實,是截至本新聞發佈日期的陳述,包括但不限於,未來計劃、估算和預測的討論以及管理層在公司發展、臨床試驗和產品商業化方面的期望和打算。

These forward‐looking statements involve numerous risks and uncertainties and actual results might differ materially from results suggested in any forward-looking statements. These risks and uncertainties include, among other things: the Company being unable to use the proceeds of the Loans as anticipated; the Company being unable to execute its business plans as intended; recent market volatility; and the state of the financial markets for the Company's securities.

此類前瞻性聲明涉及許多風險和不確定性,實際結果可能與任何前瞻性聲明所暗示的結果有所不同。這些風險和不確定性包括但不限於:公司可能無法按照預期使用貸款收益;公司可能無法按原意執行其業務計劃;近期的市場波動和公司證券的金融市場狀況。

In making the forward-looking statements in this news release, the Company has applied certain material assumptions, including without limitation, that: the Company will be able to use the proceeds of the Loans as anticipated; and the Company will be able to execute its business plans as intended.

在本新聞發佈中發表前瞻性聲明時,公司已經應用了某些實質性假設,包括但不限於:公司能夠按照預期使用貸款收益;公司將能夠按照原意執行其業務計劃。

Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial outlook that are incorporated by reference herein, except in accordance with applicable securities laws. We seek safe harbor.

雖然本公司管理層已努力確定可能導致實際結果與前瞻性聲明或前瞻性信息不同的重要因素,但可能存在其他因素使得結果不如預期、估計或意圖。因此,讀者不應過分依賴前瞻性聲明和前瞻性信息。讀者要注意,對這些信息的依賴可能不適合其他目的。公司不承擔更新任何以此處引用的前瞻性聲明、前瞻性信息或財務展望的義務,除非依照適用的證券法。感謝支持。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論